Patrick Campbell

Deepak Bhatt, MD, MPH, discusses results of the phase 2 ENTRIGUE trial and how it informs clinicians on the effects of the human FGF21 analogue in patients with severe hypertriglyceridemia.

If approved, Boehringer Ingelheim and Eli Lilly and Company's SGLT2 inhibitor would be the first agent in the class with an indication as an adjunct to diet and exercise for improving glycemic control in children with type 2 diabetes aged 10 years and older.

New research from a phase 2b trial presented at ACC 2023 suggests an oral PCSK9 inhibitor could help reduce LDL-C by 60% in patients with or at-risk for atherosclerotic cardiovascular disease.

Hear from Deepak Bhatt, MD, MPH, as he discusses how he interprets the results of the HALO trial and offers perspective on the forthcoming research related to baxdrostat.

Data from cohort 4 in REDWOOD-HCM provides the first insight into the effects of aficamten in a cohort of patients with non-obstructive hypertrophic cardiomyopathy.

Data from the phase 3 STELLAR trial indicate adding sotatercept to background therapy in PAH was associated with statistically significant improvements in 6-minute walk distance and 8 of the trial's 9 secondary endpoints, including time to death or clinical worsening.

Data from COORDINATE-Diabetes presented at ACC 2023 demonstrate the impact of a multifaceted, coordinated care approach on improving prescription rates of statins, ACEs/ARBs, and glucose-lowering medications among people with type 2 diabetes.

Mary McGowan, MD, discusses a study she presented examining the overall prevalence of patients with high-risk hypercholesterolemia who fail to meet guideline-recommended goals for LDL-C levels.

The US FDA has granted clearance to the FreeStyle Libre 2 and FreeStyle Libre 3 sensors for integration with automated insulin delivery systems. Abbott, which noted ongoing collaborations with Insulet and Tandem, expects the modified sensors to be available in the US later this year.

At ACC 2023, HCPLive editorial team sat down with Clyde Yancy, MD, to learn more about his perspective on recent and upcoming advances in cardiovascular care. In this interview, Yancy discusses his perspective on the clinical trial data surrounding renal denervation as a treatment for hypertension.

Steve Nissen, MD, sits down for an interview to discuss the clinical takeaways, design intricacies, safety signals, and more from the CLEAR Outcomes trial.

Hosts are joined by Tor Biering-Sørenson, MD, MSc, MPH, PhD, to discuss the NUDGE FLU trial and how the lessons learned can inform implementation strategies for various other types of therapies.

In the largest implementation trial ever conducted, new research from the NUDGE FLU trial suggests informing patients of the potential cardiovascular benefits associated with receipt of the flu vaccine could increase uptake among older adults.

Clyde Yancy, MD, offers insight into his keynote address and the importance of both recognizing and addressing inequities within heart failure management.

At ACC.23, our editorial team sat down with a pair of leaders in cardiometabolic health to get their perspective on the growing intersectionality of cardiovascular and chronic kidney disease and how patients have been the beneficiaries of this growing recognition.

Results of the CLEAR Outcomes trial suggests adherence to bempedoic acid was associated with a 13% relative reduction in incidence of the trial's primary endpoint of 4-point MACE, but no benefit was observed for risk of cardiovascular death or all-cause mortality in the trial.

After Eli Lilly and Company announced major reductions in list prices for multiple insulin products, the community rejoiced at the though of taking a major step forward toward equitable access to insulin. Learn more about the reaction from major organizations and those within the field.

A trio of studies presented at ATTD 2023 detail the strengths and limitations of real-time continuous glucose monitoring technologies in an array of patient populations and settings.

Data from a trio of studies presented at ATTD 2023 provide insight into the utility of the Omnipod 5 across multiple patient populations as well as use for use in inpatient settings.

Announced on March 1, Eli Lilly and Company's reduction in insulin product list prices includes non-branded insulin lispro, Rezvoglar, KwikPens, Humulin, and Humalog. The company would also be instituting an out-of-pocket cost cap of $35 for most insulin users.

Cytokinetics announced the CRL on Tuesday, as well as their intentions to forego any future clinical trials for the agent while focusing on the development of aficamten.

Ahead of the PDUFA date for omecamtiv mecarbil, HCPLive reached out to a trio of heart failure specialists to learn about their opinion of the agent based on clinical trial data, their reaction to the November 2022 AdComm vote, and whether they believe the agent warrants approval from the US FDA.

Medha Munshi, MD, discusses the concept of healthy aging in diabetes and offers perspective on contemporary trends in hurdles and optimized strategies to achieve healthy aging in people with diabetes.

A study and a subanalysis of the same study presented at ATTD 23 demonstrate use of the FreeStyle Libre flash glucose monitoring system was associated with improved treatment satisfaction and HbA1c.

A pilot study presented at ATTD 23 is providing further insight into the potential role of inhaled insulin in type 1 diabetes.

David Maahs, MD, PhD, sits down to discuss data he presented at ATTD 2023 and provide perspective on ongoing issues plaguing the diabetes community, including optimization of telehealth and addressing disparities in care.

An analysis of the DELIVER and DAPA-HF trials provides an overview of the impact of gout on heart failure outcomes and effects of dapagliflozin in this patient population.

A study from Slovenia suggests a physical activity intervention that would require physical activity every day while at school was effective for reducing BMI and reversing obesity in young children.

Using the GWTG-HF registry, new data elucidates the differences in the likelihood of being prescribed GDMT among patients hospitalized with heart failure in rural compared to urban settings.

An analysis of Veterans Affairs data from more than 20,000 people with diabetes provides an overview of the associations of CGM initiation with improved glycemic control and reduced hospitalization in this patient population.